TABLE 8.
Treatment protocols for hepatitis C (HCV) genotype 1 in HIV-HCV coinfection
| Treatment-naive | Relapser | Partial responder | Null responder | |
|---|---|---|---|---|
| Boceprevir | ||||
| HIV-HCV coinfected | ||||
| SVR rate (versus PegIFN α2b + RBV) | 63% versus 27% | – | – | – |
| Relapse rate | 3% | – | – | – |
| Duration of PegIFN α2b + RBV | Fixed 48-week duration | – | – | – |
| Duration of HCV PI | 44 weeks | |||
| PegIFN α2b + RBV lead-In | Yes: 4 weeks | |||
| HCV monoinfected | ||||
| SVR rate (versus PegIFN α2b + RBV) | 63% (n=368) versus 38% (n=363) | 69% (n=72/105) versus 29% (n=15/51) | 40% (n=23/57) versus 7% (n=2/29) | 40% (n=47) (no control)† |
| Relapse rate (versus PegIFN α2b + RBV) | 9% versus 22% | 14% (n=12/83) versus 32% (n=7/22) | 18% (n=5/28) versus 33% (n=1/3) | 14% (no control) |
| Duration of PegIFN α2b + RBV | Response guided (28 versus 48 weeks) | Response-guided (36 versus 48 weeks)* | Response-guided (36 versus 48 weeks)* | Fixed 48-week duration |
| PegIFN α2b + RBV lead-In | Yes: 4 weeks | Yes: 4 weeks | Yes: 4 weeks | Yes: 4 weeks |
| Telaprevir | ||||
| HIV-HCV coinfected | ||||
| SVR rate (versus PegIFN α2a + RBV) | 74% versus 45% | – | – | – |
| Relapse rate | – | – | – | |
| Duration of PegIFN α2a + RBV | Fixed 48-week duration | – | – | – |
| Duration of HCV PI | 12 weeks | |||
| PegIFN α2a + RBV lead-In | No | – | – | – |
| HCV monoinfected | ||||
| SVR rate (versus PegIFN α2a + RBV) | 75% (n=271/363) versus 44% (n=158/361) | 86% (n=245/286) versus 24% (n=16/68) | 57% (n=55/97) versus 15% (n=4/27) | 31% (n=46/147) versus 5% (n=2/37) |
| Relapse rate (versus PegIFN α2a + RBV) | 9% (n=27/314) versus 28% (n=64/229) | 3% (n=19/278) versus 63% (n=27/43) | 20% (n=14/71) versus 0% (n=0/4) | 24% (n=15/62) versus 50% (n=2/4) |
| Duration of PegIFN α2a + RBV | Response-guided (24 or 48 weeks) | Response-guided (24 versus 48 weeks) | Fixed 48-week duration | Fixed 48-week duration |
| Duration of HCV PI | 12 weeks | 12 weeks | 12 weeks | 12 weeks |
| PegIFN α2a + RBV lead-in | No | No | No | No |
*
If cirrhotic, then 48 weeks fixed duration,
†
Interim results from rollover study (132). PegIFN α2a Pegylated interferon alfa-2a; PI Protease inhibitor; RBV Ribavirin; SVR Sustained virological response